All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Vicept Therapeutics Inc., of Malvern, Pa., said results from a Phase II trial testing the dose-response relationship of two concentrations of V-101, a topical cream for treating Type I rosacea demonstrated a statistically significant improvement (p < 0.01) in the primary endpoint, defined as a reduction in facial erythema over a 12-hour period vs. placebo cream. V-101 also demonstrated a safety profile similar to placebo.